A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1/2 Recruiting
245 enrolled
MK-3475-06F
Phase 1/2 Recruiting
60 enrolled
TUPELO
Phase 1/2 Recruiting
67 enrolled
TAQE
Phase 1/2 Recruiting
93 enrolled
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/2 Recruiting
94 enrolled
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/2 Recruiting
124 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/2 Recruiting
49 enrolled
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/2 Recruiting
150 enrolled
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Phase 1/2 Recruiting
129 enrolled
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Phase 1/2 Recruiting
92 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/2 Recruiting
49 enrolled
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Phase 1/2 Recruiting
71 enrolled
OrigAMI-1
Phase 1/2 Recruiting
225 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
MK-3475-06C
Phase 1/2 Recruiting
160 enrolled
GPC3
Phase 1/2 Recruiting
590 enrolled
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Phase 1/2 Recruiting
92 enrolled
The KN510713 Study in Combination With mFOLFIRINOX
Phase 1/2 Recruiting
30 enrolled
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Phase 1/2 Recruiting
86 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
595 enrolled
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/2 Recruiting
45 enrolled
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/2 Recruiting
102 enrolled
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Phase 1/2 Recruiting
138 enrolled
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Phase 1/2 Recruiting
31 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Phase 1/2 Recruiting
193 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Recruiting
60 enrolled
RHEA-1
Phase 1/2 Recruiting
304 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 5 FDA
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
MK-3475-06D
Phase 1/2 Recruiting
210 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
PANGEA
Phase 1/2 Recruiting
104 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
MK-3475-06E
Phase 1/2 Recruiting
298 enrolled
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
53 enrolled
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting
61 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
DUET-HCC
Phase 1/2 Recruiting
30 enrolled